New forms of old drugs: Improving without changing

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 6, 2015, Pages 830-846

  Domingos, Sofia ^a   André, Vânia ^a,b   Quaresma, Sílvia ^a   Martins, Inês C B ^a   Minas Da Piedade, M Fátima ^a,c   Duarte, Maria Teresa ^a  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

Author keywords

API metal coordination; drug performance; multicomponent crystals; solid forms; structure property relationship

Indexed keywords

ACETYLSALICYLIC ACID; ADEFOVIR DIPIVOXIL; AMOXICILLIN PLUS CLAVULANIC ACID; BLONANSERIN; CARBAMAZEPINE; CELECOXIB; CINNAMIC ACID; FLUOXETINE; FLURBIPROFEN; GABAPENTIN; IBUPROFEN; LACTAM; LAMIVUDINE; LIDOCAINE; MELOXICAM; NABUMETONE; NALIDIXIC ACID; NEW DRUG; NICOTINAMIDE; PARACETAMOL; PIPERACILLIN; PYRAZINAMIDE; RISPERIDONE; RITONAVIR; SACCHARIN; SULFACETAMIDE; TEMOZOLOMIDE; UNINDEXED DRUG; VENLAFAXINE; ZIDOVUDINE; DRUG; IONIC LIQUID; METAL;

ANTIMICROBIAL ACTIVITY; ARTICLE; BIO INSPIRED METAL ORGANIC FRAMEWORK; BIOTECHNOLOGICAL PROCEDURES; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG SYNTHESIS; HUMAN; NONHUMAN; SHELF LIFE; SOLID STATE; TABLET; CHEMISTRY; CRYSTALLIZATION; MEDICINAL CHEMISTRY; PHARMACEUTICS;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; HUMANS; IONIC LIQUIDS; METALS; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84929338792     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12384     Document Type: Article

References (170)

1. Elder DP, et al. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility. Int J Pharm 2013; 453: 88-100.
2. Biradha K, et al. Recent developments in crystal engineering. Cryst Growth Des 2011; 11: 875-886.
3. Braga D, et al. The growing world of crystal forms. Chem Commun 2010; 46: 6232-6242.
4. Desiraju GR,. Crystal engineering: a brief overview. J Chem Sci 2010; 122: 667-675.
5. Nangia A,. Supramolecular chemistry and crystal engineering. J Chem Sci 2010; 122: 295-310.
6. Aitipamula S, et al. Polymorphs, salts, and cocrystals: what's in a name? Cryst Growth Des 2012; 12: 2147-2152.
7. Smith AJ, et al. Improving lithium therapeutics by crystal engineering of novel ionic cocrystals. Mol Pharm 2013; 10: 4728-4738.
8. Shan N, Zaworotko MJ,. The role of cocrystals in pharmaceutical science. Drug Discov Today 2008; 13: 440-446.
9. Almarsson O, Zaworotko MJ,. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem Commun 2004; 17: 1889-1896.
10. Tomaszewska I, et al. Pharmaceutical characterisation and evaluation of cocrystals: Importance of in vitro dissolution conditions and type of coformer. Int J Pharm 2013; 453: 380-388.
11. Lahiani-Skiba M, et al. Improvement in the water solubility and stability of 4ASA by the use of cyclodextrins. J Inclusion Phenom Macrocyclic Chem 2011; 69: 327-331.
12. Chency ML, et al. Effects of crystal form on solubility and pharmacokinetics: a crystal engineering case study of lamotrigine. Cryst Growth Des 2010; 10: 394-405.
13. Braga D, et al. Making crystals from crystals: a solid-state route to the engineering of crystalline materials, polymorphs, solvates and co-crystals; considerations on the future of crystal engineering. Eng Crystalline Mater Properties 2008; NATO Science for Peace and Security Series B: Physics and Biophysics: 131-156.
14. Desiraju GR,. Crystal engineering: a holistic view. Angewandte Chemie-Int Ed 2007; 46: 8342-8356.
15. Desiraju GR,. Crystal Engineering: The Design of Organic Solids. Amsterdam: Elsevier, 1989.
16. Desiraju GR,. Crystal engineering: structure, design and function. Curr Opin Solid State Mater Sci 2009; 13: 35.
17. Schmidt GMJ,. Photo dimerization in the solid state. Pure Appl Chem 1971; 27: 647-678.
18. Lehn JM,. Cryptates-inclusion complexes of macropolycyclic receptor molecules. Pure Appl Chem 1978; 50: 871-892.
19. Lehn JM, Rigault A,. Helicates-tetranuclear and pentanuclear double helix complexes of CU-I and poly(bipyridine) strands. Angewandte Chemie-Int Ed Eng 1988; 27: 1095-1097.
20. Lehn JM,. Supramolecular chemistry-scope and perspectives molecules, supermolecules, and molecular devices. Angewandte Chemie-Int Ed Eng 1988; 27: 89-112.
21. Dunitz JD,. Phase-transitions in molecular-crystals from a chemical viewpoint. Pure Appl Chem 1991; 63: 177-185.
22. Bernstein J,. Polymorphism-a perspective. Cryst Growth Des 2011; 11: 632-650.
23. Jie L, et al. Polymorphism of pharmaceutical molecules: perspectives on nucleation. Front Chem Eng China 2010; 4: 37-44.
24. Braga D, et al. Crystal polymorphism and multiple crystal forms. Mol Netw 2009; 132: 25-50.
25. Bond AD, et al. On the polymorphism of aspirin. Angewandte Chemie-Int Ed 2007; 46: 615-617.
26. Karpinski PH,. Polymorphism of active pharmaceutical ingredients. Chem Eng Technol 2006; 29: 233-237.
27. Dematos LL, et al. Solvent influences on metastable polymorph lifetimes: Real-time interconversions using energy dispersive X-ray diffractometry. J Pharm Sci 2007; 96: 1069-1078.
28. Karki S, et al. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding. Mol Pharm 2007; 4: 347-354.
29. Pudipeddi M, Serajuddin ATM,. Trends in solubility of polymorphs. J Pharm Sci 2005; 94: 929-939.
30. Andre V, et al. Transforming aspirin into novel molecular salts of salicylic acid. Struct Chem 2014; 25: 707-714.
31. Braga D, et al. Molecular salts of anesthetic lidocaine with dicarboxylic acids: solid-state properties and a combined structural and spectroscopic study. Cryst Growth Des 2013; 13: 2564-2572.
32. Kumar A, et al. (2008) New perindopril salts e.g. perindopril phthalic acid salt, perindopril tartaric acid salt, perindopril phosphate and perindopril camphor sulfonate, useful in therapies of arterial hypertension and cardiac insufficiency. Ipca Lab Ltd.
33. Serajuddin ATM,. Salt formation to improve drug solubility. Adv Drug Deliv Rev 2007; 59: 603-616.
34. Black SN, et al. Structure, solubility, screening, and synthesis of molecular salts. J Pharm Sci 2007; 96: 1053-1068.
35. Childs SL, et al. The salt-cocrystal continuum: the influence of crystal structure on ionization state. Mol Pharm 2007; 4: 323-338.
36. Trask AV, et al. Screening for crystalline salts via mechanochemistry. Chem Commun 2006; 1: 51-53.
37. Giron D,. Characterisation of salts of drug substances. J Therm Anal Calorimetry 2003; 73: 441-457.
38. Perman JA, et al. Cocrystal controlled solid-state synthesis of a rigid tetracarboxylate ligand that pillars both square grid and Kagome lattice layers. Crystengcomm 2011; 13: 3130-3133.
39. Elbagerma MA, et al. Characterization of new cocrystals by Raman spectroscopy, powder X-ray diffraction, differential scanning calorimetry, and transmission Raman spectroscopy. Cryst Growth Des 2010; 10: 2360-2371.
40. Bethune SJ, et al. Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility. Cryst Growth Des 2009; 9: 3976-3988.
41. Friscic T, MacGillivray LR,. Engineering cocrystal and polymorph architecture via pseudoseeding. Chem Commun 2009; 7: 773-775.
42. Friscic T, Jones W,. Recent advances in understanding the mechanism of cocrystal formation via grinding. Cryst Growth Des 2009; 9: 1621-1637.
43. Good DJ, Rodriguez-Hornedo N,. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des 2009; 9: 2252-2264.
44. Reddy LS, et al. Cocrystals and salts of gabapentin: pH dependent cocrystal stability and solubility. Cryst Growth Des 2009; 9: 378-385.
45. Schartman RR,. On the thermodynamics of cocrystal formation. Int J Pharm 2009; 365: 77-80.
46. Connelly PR, et al. (2008) Co-crystal, useful e.g. for treating hepatitis C virus infection and molecular modeling to identify other possible co-crystal forms, comprises vertex hepatitis C virus protease inhibitor, salicylic acid, aminosalicylic acid or oxalic acid. Vertex Pharm Inc; Connelly P R.
47. He GW, et al. Screening for cocrystallization tendency: the role of intermolecular interactions. J Phys Chemistry B 2008; 112: 9890-9895.
48. Takata N, et al. Cocrystal screening of stanolone and mestanolone using slurry crystallization. Cryst Growth Des 2008; 8: 3032-3037.
49. Aakeroy CB, et al. Cocrystal or salt: does it really matter? Mol Pharm 2007; 4: 317-322.
50. Friscic T, Jones W,. Cocrystal architecture and properties: design and building of chiral and racemic structures by solid-solid reactions. Faraday Discuss 2007; 136: 167-178.
51. Wenger M, Bernstein J,. Cocrystal design gone awry? A new dimorphic hydrate of oxalic acid. Mol Pharm 2007; 4: 355-359.
52. Friscic T, et al. Exploring cocrystal-cocrystal reactivity via liquid-assisted grinding: the assembling of racemic and dismantling of enantiomeric cocrystals. Chem Commun 2006; 48: 5009-5011.
53. Jones W, et al. Pharmaceutical cocrystals: an emerging approach to physical property enhancement. MRS Bull 2006; 31: 875-879.
54. Trask AV, et al. Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration. Cryst Growth Des 2005; 5: 1013-1021.
55. Grepioni F, et al. Ionic co-crystals of racetams: solid-state properties enhancement of neutral active pharmaceutical ingredients via addition of Mg2+ and Ca2+ chlorides. Crystengcomm 2014; 16: 5887-5896.
56. Martinez-Alejo JM, et al. A twist in cocrystals of salts: changes in packing and chloride coordination lead to opposite trends in the biopharmaceutical performance of fluoroquinolone hydrochloride cocrystals. Cryst Growth Des 2014; 14: 3078-3095.
57. Wouters J, et al. Novel pharmaceutical compositions through co-crystallization of racetams and Li+ salts. Crystengcomm 2013; 15: 8898-8902.
58. Braga D, et al. Combining piracetam and lithium salts: ionic co-crystals and co-drugs? Chem Commun 2012; 48: 8219-8221.
59. Braga D, et al. From unexpected reactions to a new family of ionic co-crystals: the case of barbituric acid with alkali bromides and caesium iodide. Chem Commun 2010; 46: 7715-7717.
60. Quaresma S, et al. Gabapentin coordination networks: mechanochemical synthesis and behavior under shelf conditions. Cryst Growth Des 2013; 13: 5007-5017.
61. André V, et al. Mechanosynthesis of the metallodrug bismuth subsalicylate from Bi(2)O(3) and structure of bismuth salicylate without auxiliary organic ligands. Angewandte Chemie-Int Ed 2011; 50: 7858-7861.
62. An JY, et al. Cation-triggered drug release from a porous zinc-adeninate metal-organic framework. J Am Chem Soc 2009; 131: 8376-8377.
63. Horcajada P, et al. Flexible porous metal-organic frameworks for a controlled drug delivery. J Am Chem Soc 2008; 130: 6774-6780.
64. Horcajada P, et al. Metal-organic frameworks in biomedicine. Chem Rev 2012; 112: 1232-1268.
65. Horcajada P, et al. Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging. Nat Mater 2010; 9: 172-178.
66. McKinlay AC, et al. BioMOFs: metal-organic frameworks for biological and medical applications. Angewandte Chemie-Int Ed 2010; 49: 6260-6266.
67. Miller SR, et al. Biodegradable therapeutic MOFs for the delivery of bioactive molecules. Chem Commun 2010; 46: 4526-4528.
68. Llewellyn PL, et al. Prediction of the conditions for breathing of metal organic framework materials using a combination of X-ray powder diffraction, microcalorimetry, and molecular simulation. J Am Chem Soc 2008; 130: 12808-12814.
69. Horcajada P, et al. Metal-organic frameworks as efficient materials for drug delivery. Angewandte Chemie-Int Ed 2006; 45: 5974-5978.
70. Miroshnyk I, et al. Pharmaceutical co-crystals-an opportunity for drug product enhancement. Expert Opin Drug Deliv 2009; 6: 333-341.
71. Qiao N, et al. Pharmaceutical cocrystals: an overview. Int J Pharm 2011; 419: 1-11.
72. Asija R, et al. Pharmaceutical cocrystals: an overview. J Drug Discov Ther 2013; 1: 10-14.
73. Allen FH,. The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr B 2002; 58: 380-388.
74. Desiraju GR,. Supramolecular synthons in crystal engineering-a new organic-synthesis. Angewandte Chemie-Int Ed Eng 1995; 34: 2311-2327.
75. Vishweshwar P, et al. Pharmaceutical co-crystal. J Pharm Sci 2006; 95: 499-516.
76. Wood PA, et al. Knowledge-based approaches to co-crystal design. Crystengcomm 2014; 16: 5839-5848.
77. Blagden N, et al. Pharmaceutical co-crystals-are we there yet? Cryst EngComm 2014; 16: 5753-5761.
78. Jayasankar A, et al. Mechanisms by which moisture generates cocrystals. Mol Pharm 2007; 4: 360-372.
79. Tanaka K, Toda F,. Solvent-free organic synthesis. Chem Rev 2000; 100: 1025-1074.
80. Trask AV, et al. Solvent-drop grinding: green polymorph control of cocrystallisation. Chem Commun 2004; 7: 890-891.
81. Braga D, et al. Mechanochemical preparation of co-crystals. Chem Soc Rev 2013; 42: 7638-7648.
82. James SL, et al. Mechanochemistry: opportunities for new and cleaner synthesis. Chem Soc Rev 2012; 41: 413-447.
83. Friscic T, et al. Ion- and liquid-assisted grinding: improved mechanochemical synthesis of metal-organic frameworks reveals salt inclusion and anion templating. Angewandte Chemie-Int Ed 2010; 49: 712-715.
84. Friscic T,. New opportunities for materials synthesis using mechanochemistry. J Mater Chem 2010; 20: 7599-7605.
85. Friscic T, et al. Screening for inclusion compounds and systematic construction of three-component solids by liquid-assisted grinding. Angewandte Chemie-Int Ed 2006; 45: 7546-7550.
86. Shamshina JL, et al. Ionic liquids in drug delivery. Expert Opin Drug Deliv 2013; 10: 1-15.
87. Marrucho IM, et al. Ionic liquids in pharmaceutical applications. Ann Rev Chem Biomol Eng 2014; 5: 527-546.
88. Ferraz R, et al. Development of novel ionic liquids based on ampicillin. Medchemcomm 2012; 3: 494-497.
89. Bernstein J,. Polymorphism in Molecular Crystals. Oxford: Clarendon Press, 2002.
90. Threlfall TL,. Analysis of organic polymorphs-a review. Analyst 1995; 120: 2435-2460.
91. Bis JA, et al. Concomitant and conformational polymorphism, conformational isomorphism, and phase relationships in 4-cyanopyridine center dot 4,4 '-biphenol cocrystals. Cryst Growth Des 2006; 6: 1048-1053.
92. Teychene S, et al. Crystallization of eflucimibe drug in a solvent mixture: effects of process conditions on polymorphism. Cryst Growth Des 2004; 4: 971-977.
93. Alleso M, et al. Solvent diversity in polymorph screening. J Pharm Sci 2008; 97: 2145-2159.
94. Moribe K, et al. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation. Adv Drug Deliv Rev 2008; 60: 328-338.
95. Beckmann W,. Seeding the desired polymorph: background, possibilities, limitations, and case studies. Org Process Res Dev 2000; 4: 372-383.
96. Muller M, et al. Process development strategy to ascertain reproducible API polymorph manufacture. Cryst Growth Des 2006; 6: 946-954.
97. An J-H, Kim W-S,. Antisolvent crystallization using ionic liquids as solvent and antisolvent for polymorphic design of active pharmaceutical ingredient. Cryst Growth Des 2013; 13: 31-39.
98. An J-H, et al. Application of ionic liquid to polymorphic design of pharmaceutical ingredients. Cryst Growth Des 2010; 10: 3044-3050.
99. Stahly GP,. Diversity in single- and multiple-component crystals. The search for and prevalence of polymorphs and cocrystals. Cryst Growth Des 2007; 7: 1007-1026.
100. Karabas I, et al. Analysis and stability of polymorphs in tablets: the case of Risperidone. Talanta 2007; 71: 1382-1386.
101. Brittain HG,. Polymorphism in Pharmaceutical Solids. New York: Taylor & Francis, 1999.
102. Bauer J, et al. Ritonavir: an extraordinary example of conformational polymorphism. Pharm Res 2001; 18: 859-866.
103. Fleischman SG, et al. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. Cryst Growth Des 2003; 3: 909-919.
104. Grzesiak AL, et al. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci 2003; 92: 2260-2271.
105. Price CP, et al. Polymorphism of nabumetone. Cryst Growth Des 2002; 2: 501-503.
106. Prabhakar C, et al. Process research and structural studies on nabumetone. Org Process Res Dev 1999; 3: 121-125.
107. Babu NJ, et al. Polymorphs and polymorphic cocrystals of temozolomide. Chem Asian J 2008; 3: 1122-1133.
108. Lee MK, et al. Novel polymorphic form of adefovir dipivoxil derived from polymer-directed crystallization. Pharmazie 2011; 66: 766-770.
109. Gangavaram S, et al. Polymorphs and cocrystals of nalidixic acid. Cryst Growth Des 2012; 12: 4963-4971.
110. Surwase SA, et al. Indomethacin: new polymorphs of an old drug. Mol Pharm 2013; 10: 4472-4480.
111. Najar AA, Azim Y,. Pharmaceutical co-crystals: a new paradigm of crystal engineering. J Indian Ins Sci 2014; 94: 45-67.
112. Steed JW,. The role of co-crystals in pharmaceutical design. Trends Pharmacol Sci 2013; 34: 185-193.
113. Wenger M, Bernstein J,. An alternate crystal form of gabapentin: a cocrystal with oxalic acid. Cryst Growth Des 2008; 8: 1595-1598.
114. Thakuria R, et al. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm 2013; 453: 101-125.
115. Maddileti D, et al. High solubility crystalline pharmaceutical Forms of blonanserin. Cryst Growth Des 2014; 14: 2557-2570.
116. Porter WW, et al. Polymorphism in carbamazepine cocrystals. Cryst Growth Des 2008; 8: 14-16.
117. Hickey MB, et al. Performance comparison of a co-crystal of carbamazepine with marketed product. Eur J Pharm Biopharm 2007; 67: 112-119.
118. Chow SF, et al. Simultaneously improving the mechanical properties, dissolution performance, and hygroscopicity of ibuprofen and flurbiprofen by cocrystallization with nicotinamide. Pharm Res 2012; 29: 1854-1865.
119. Karki S, et al. Improving mechanical properties of crystalline solids by cocrystal formation: new compressible forms of paracetamol. Adv Mater 2009; 21: 3905-3909.
120. Andre V, et al. Revisiting paracetamol in a quest for new co-crystals. Crystengcomm 2012; 14: 5005-5014.
121. Lee HG, et al. Cocrystal intrinsic dissolution behavior using a rotating disk. J Pharm Sci 2011; 100: 1736-1744.
122. Andre V, et al. On the track of new multicomponent gabapentin crystal forms: synthon competition and pH stability. Cryst Growth Des 2011; 11: 2325-2334.
123. Maheshwari C, et al. Tailoring aqueous solubility of a highly soluble compound via cocrystallization: effect of coformer ionization, pHmax, and solute-solvent interactions. Cryst Eng Comm 2012; 14: 4801-4811. accepted.
124. Cheney ML, et al. Supramolecular architectures of meloxicam carboxylic acid cocrystals, a crystal engineering case study. Cryst Growth Des 2010; 10: 4401-4413.
125. Weyna DR, et al. Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation. Mol Pharm 2012; 9: 2094-2102.
126. Cheney ML, et al. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. J Pharm Sci 2011; 100: 2172-2181.
127. Bhatt PM, et al. 2009. New co-crystal of lamivudine with zidovudine comprising one molecule each of lamivudine, zidovudine and water, useful in the treatment of HIV infections in humans. Lupin Ltd.
128. Bhatt PM, et al. Co-crystals of the anti-HIV drugs lamivudine and zidovudine. Cryst Growth Des 2009; 9: 951-957.
129. Remenar JF, et al. Celecoxib: nicotinamide dissociation: using excipients to capture the cocrystal's potential. Mol Pharm 2007; 4: 386-400.
130. Planta Salaman CR, et al. 2011. New co-crystal comprising venlafaxine (either as free base/its salt) and celecoxib, useful to treat e.g. chronic pain and depression in patients with chronic musculo-skeletal inflammatory illness (osteoarthritis/rheumatoid arthritis). Lab Del Esteve Sa.
131. Soler Ranzani L, et al. 2011. Composition, useful for treating e.g. pain, preferably acute pain, chronic pain, neuropathic pain, nociceptive pain, and hyperalgesia, comprises co-crystal of (rac)-tramadol hydrochloride-celecoxib, and solubility enhancer polymer. Lab Del Esteve Sa.
132. Nugrahani I, et al. The antibiotic potency of amoxicillin-clavulanate co-crystal. Int J Pharmacol 2007; 3: 475-481.
133. Evora AOL, et al. Pyrazinamide-diflunisal: a new dual-drug co-crystal. Cryst Growth Des 2011; 11: 4780-4788.
134. Hough WL, et al. The third evolution of ionic liquids: active pharmaceutical ingredients. New J Chem 2007; 31: 1429-1436.
135. Rogers RD, et al. (2012) Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients. (Vol. US 8,232,265 B2).
136. Ferraz R, et al. Development of novel IL-APIs based on ampicillin derivatives. Med Chem Commun 2012; 3: 494-497.
137. Florindo C, et al. Evaluation of solubility and partition properties of ampicillin-based ILs. Int J Pharm 2013; 456: 553-559.
138. Childs SL, et al. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc 2004; 126: 13335-13342.
139. Braga D, et al. Ionic co-crystals of organic molecules with metal halides: a new prospect in the solid formulation of active pharmaceutical ingredients. Cryst Growth Des 2011; 11: 5621-5627.
140. Ong TT, et al. 2:1 cocrystals of homochiral and achiral amino acid zwitterions with Li+ salts: water-stable zeolitic and diamondoid metal-organic materials. J Am Chem Soc 2011; 133: 9224-9227.
141. Delori A, et al. The role of mechanochemistry and supramolecular design in the development of pharmaceutical materials. Crystengcomm 2012; 14: 2350-2362.
142. Ma Z, Moulton B,. Supramolecular medicinal chemistry: mixed-ligand coordination complexes. Mol Pharm 2007; 4: 373-385.
143. Braga D, et al. Simple and quantitative mechanochemical preparation of the first zinc and copper complexes of the neuroleptic drug gabapentin. Crystengcomm 2008; 10: 469-471.
144. Braga D, et al. Simple and quantitative mechanochemical preparation of a porous crystalline material based on a 1D coordination network for uptake of small molecules. Angewandte Chemie-Int Ed 2006; 45: 142-146.
145. Yuan W, et al. High reactivity of metal-organic frameworks under grinding conditions: parallels with organic molecular materials. Angewandte Chemie-Int Ed 2010; 49: 3916-3919.
146. Bowmaker GA, et al. The role of short-range diffusion in solvent-assisted mechanochemical synthesis of metal complexes. Dalton Trans 2008; 39: 5290-5292.
147. Belcher WJ, et al. Channel-containing 1D coordination polymers based on a linear dimetallic spacer. Chem Commun 2002; 15: 1602-1603.
148. Braga D, Grepioni F,. Reactions between or within molecular crystals. Angewandte Chemie-Int Ed 2004; 43: 4002-4011.
149. Chow EHH, et al. Mechanochemistry of magnesium oxide revisited: facile derivatisation of pharmaceuticals using coordination and supramolecular chemistry. Chem Commun 2010; 46: 6368-6370.
150. Braga D, et al. Drug-containing coordination and hydrogen bonding networks obtained mechanochemically. Crystengcomm 2009; 11: 2618-2621.
151. Friscic T, et al. A rational approach to screen for hydrated forms of the pharmaceutical derivative magnesium naproxen using liquid-assisted grinding. Crystengcomm 2011; 13: 3125-3129.
152. Guo ZJ, Sadler PJ,. Metals in medicine. Angewandte Chemie-Int Ed 1999; 38: 1513-1531.
153. Ge R, Sun H,. Bioinorganic chemistry of bismuth and antimony: target sites of metallodrugs. Acc Chem Res 2007; 40: 267-274.
154. Andrews PC, et al. Towards a structural understanding of the anti-ulcer and anti-gastritis drug bismuth subsalicylate. Angewandte Chemie-Int Ed 2006; 45: 5638-5642.
155. Janiak C, Vieth JK,. MOFs, MILs and more: concepts, properties and applications for porous coordination networks (PCNs). New J Chem 2010; 34: 2366-2388.
156. Notash B, et al. Anion-controlled structural motif in one-dimensional coordination networks via cooperative weak noncovalent interactions. Crystengcomm 2012; 14: 6788-6796.
157. Keskin S, Kizilel S,. Biomedical applications of metal organic frameworks. Ind Eng Chem Res 2011; 50: 1799-1812.
158. Ferey G, Serre C,. Large breathing effects in three-dimensional porous hybrid matter: facts, analyses, rules and consequences. Chem Soc Rev 2009; 38: 1380-1399.
159. Della Rocca J, et al. Nanoscale metal-organic frameworks for biomedical imaging and drug delivery. Acc Chem Res 2011; 44: 957-968.
160. Sun C-Y, et al. Metal-organic frameworks as potential drug delivery systems. Expert Opin Drug Deliv 2013; 10: 89-101.
161. Imaz I, et al. Metal-biomolecule frameworks (MBioFs). Chem Commun 2011; 47: 7287-7302.
162. O'Keeffe M,. Design of MOFs and intellectual content in reticular chemistry: a personal view. Chem Soc Rev 2009; 38: 1215-1217.
163. Ferey G,. Hybrid porous solids: past, present, future. Chem Soc Rev 2008; 37: 191-214.
164. Millange F, et al. Effect of the nature of the metal on the breathing steps in MOFs with dynamic frameworks. Chem Commun 2008; 39: 4732-4734.
165. Kuroda R, et al. Varied charge-transfer complex crystals formed between diols and benzoquinone in the solid and solution states. Crystengcomm 2008; 10: 1881-1890.
166. Dietzel PDC, et al. Base-induced formation of two magnesium metal-organic framework compounds with a bifunctional tetratopic ligand. Eur J Inorg Chem 2008; 23: 3624-3632.
167. An J, et al. Cation-triggered drug release from a porous zinc-adeninate metal-organic framework. J Am Chem Soc 2009; 131: 8376-8377.
168. Babarao R, Jiang J,. Unraveling the energetics and dynamics of ibuprofen in mesoporous metal-organic frameworks. J Phys Chem C 2009; 113: 18287-18291.
169. Pichon A, et al. Solvent-free synthesis of a microporous metal-organic framework. Crystengcomm 2006; 8: 211-214.
170. Perman JA, et al. Cocrystal controlled solid-state synthesis of a thermally stable nicotinate analogue that sustains an isostructural series of porous metal-organic materials. Cryst Growth Des 2009; 9: 5021-5023.